Utilisation de la cabergoline dans la maladie de Cushing non contrôlée

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Annales D Endocrinologie

• Publication date

  2005-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S0003-4266(06)72611-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cabergoline plus lanreotide for ectopic Cushing's syndrome.

  2005cited by this paper
• Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors.

  2004cited by this paper
• Dopamine receptor expression and function in corticotroph pituitary tumors.

  2004cited by this paper
• Cushing's syndrome.

  2001cited by this paper
• ACTH silent adenoma shrinking under cabergoline.

  2001cited by this paper
• Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline

  1999cited by this paper
• Large and invasive silent corticotroph-cell adenoma with elevated serum ACTH: a case report.

  1998cited by this paper
• The medical treatment of Cushing's syndrome.

  1993cited by this paper
• Dopamine agonists and pituitary tumor shrinkage.

  1992cited by this paper
• A pituitary adenoma secreting high molecular weight adrenocorticotropin without evidence of Cushing's disease.

  1987cited by this paper
• The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome.

  1980cited by this paper

• Effectiveness of Medical Treatment of Cushing’s Disease: A Systematic Review and Meta-Analysis

  2021cites this paper
• Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis

  2018cites this paper
• Current strategies for the treatment of severe Cushing’s syndrome

  2016cites this paper
• Current approaches to the pharmacological management of Cushing's disease.

  2015cites this paper
• Cushing's disease and high dose cabergoline monotherapy: rapid and sustained clinical and biochemical improvement, with reversal of diabetes, hypertension and infertility.

  2015cites this paper
• Macroadénome hypophysaire coticotrope : à propos d’un cas

  2013cites this paper
• Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy.

  2010cites this paper
• Cabergoline monotherapy in the long-term treatment of Cushing's disease.

  2010cites this paper
• Treatment of Cushing disease: overview and recent findings

  2010cites this paper
• Medical Treatment in Cushing’s Syndrome: Dopamine Agonists and Cabergoline

  2010cites this paper
• Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome

  2009cites this paper
• Pituitary-directed medical treatment of Cushing’s disease

  2009cites this paper
• Medical Therapy for Cushing’s Disease – Past and Future Modes of Treatment

  2008cites this paper
• Pituitary-targeted medical therapy of Cushing's disease

  2008cites this paper
• Adénome corticotrope

  2008cites this paper
• [New medical treatments in pituitary adenomas].

  2008cites this paper
• Advances in medical treatment of Cushing’s disease

  2007cites this paper
• Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.

  2007cites this paper
• Pharmacological management of Cushing's syndrome: an update.

  2007cites this paper